The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Stocks hitting 52-week highs on Aug. 13)

  • Iradimed Corp IRMD
  • SurModics, Inc. SRDX

Down In The Dumps

(Stocks hitting 52-week lows on Aug. 13)

  • Acasti Pharma ACST
  • Achaogen Inc AKAO
  • Agile Therapeutics Inc AGRX
  • Arsanis Inc ASNS(reported a wider-than-expected loss for its Q2)
  • aTyr Pharma Inc LIFE
  • Aytu BioScience AYTU (1-for-20 reverse stock split became effective)
  • Cleveland BioLabs, Inc. CBLI
  • DelMar Pharmaceuticals Inc DMPI
  • IntelliPharmaCeutics Intl Inc (USA) IPCI
  • Osiris Therapeutics, Inc. OSIR
  • Portola Pharmaceuticals PTLA
  • Puma Biotechnology Inc PBYI
  • Surface Oncology Inc SURF
  • Synlogic Inc SYBX
  • Titan Medical Inc. TMDI(reacted to the announcement of Q2 results)
  • VBI Vaccines Inc VBIV

Stocks In Focus

Stocks Reacting To Earnings

VolitionRX Ltd VNRX reported a loss of 15 cents per share for the second quarter, wider than the loss of 13 cents per share last year. Analysts, on average, estimated a loss of 14 cents per share. Cash and cash equivalents as of June 30, 2018 totaled $11.9 million.

The stock rose 3.66 percent to $1.98 in after-hours session.

Cesca Therapeutics Inc KOOL reported second-quarter net revenues of $2 million compared to $3.5 million last year, with the decline attributed to lower AXP sales due to a change in a distributor in China, lower BioArchive device sales and the termination of a royalty payment agreement last year.

The loss per share widened from 12 cents in Q217 to $1.73 in Q218. The stock jumped 11.76 percent to $11.76 percent in after-hours trading.

See Also: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

ENDRA Life Sciences Inc NDRA reported a loss of 47 cents per share for its second quarter compared to a loss of 59 cents per share in the year-ago quarter.

The stock gained 4.01 percent to $2.36 in after-hours trading.

Acer Therapeutics Inc ACER said its second-quarter loss narrowed from $1.29 in Q217 to 64 cents per share in Q218. The consensus estimate had called for a loss of 55 cents per share.

The stock jumped 9.03 percent to $31.62 in after-hours trading.

On The Radar

Earnings

  • Athenex Inc ATNX Q2 EPS $(0.58) Misses $(0.48) Estimate, Sales $11.6M Miss $14.42M Estimate
  • Array Biopharma Inc ARRY Q4 EPS $(0.25) Misses $(0.24) Estimate, Sales $35.4M Miss $38.73M Estimate
  • Bioanalytical Systems, Inc. BASI(before the market open)
  • Cancer Genetics Inc CGIX Q2 EPS $(0.13) Beats $(0.16) Estimate, Sales $7.036M Miss $8.3M Estimate
  • Eyenovia Inc EYEN Q2 EPS $(0.33) Beats $(0.42) Est.
  • Urogen Pharma Ltd URGN Q2 EPS $(1.14) Misses $(0.89) Estimate, Sales $364K
  • Neuronetics Inc STIM Q2 EPS $(30.60) Misses $(0.84) Estimate, Sales $13.252M Beat $12.32M Estimate
  • Onconova Therapeutics Inc ONTX Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $485K Beat $220K Estimate
  • OptiNose Inc OPTN Q2 EPS $(0.64) Beats $(0.77) Estimate, Sales $1.274M Beat $1.25M Estimate
  • Aerpio Pharmaceuticals Inc ARPO Q2 EPS $(0.22) Beats $(0.23) Est., Sales $1.33M May Not Compare To $670K Est.
  • aTyr Pharma Inc LIFE (after the market close)
  • Cytori Therapeutics Inc CYTX (after the market close)
  • Biocept Inc BIOC (after the market close)
  • Reshape Lifesciences Inc RSLS (after the market close)
  • RXi Pharmaceuticals Corp RXII (after the market close)
  • Precision Therapeutics Inc AIPT (after the market close)

IPO

Aridis Pharmaceuticals priced its offering of 2 million shares at $13 per share, at the low end of the estimated price range of $13-$15. The shares will begin trading on the Nasdaq under the ticker symbol ARDS.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
▲▼
ticker
▲▼
name
▲▼
Actual EPS
▲▼
EPS Surprise
▲▼
Actual Rev
▲▼
Rev Surprise
▲▼
Posted In: BiotechEarningsNewsTop StoriesTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!